|
|
| | H-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2 Basic information |
| Product Name: | H-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2 | | Synonyms: | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE-38 (16-38), HUMAN, OVINE, RAT;PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE-38 (16-38) (HUMAN, CHICKEN, MOUSE, OVINE, PORCINE, RAT);PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (16-38) (HUMAN, OVINE, RAT);PACAP (16-38) (HUMAN, OVINE, RAT);PACAP-38 (16-38) (HUMAN, CHICKEN, MOUSE, OVINE, PORCINE, RAT);PACAP-38 (16-38), HUMAN, OVINE, RAT;H-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2;GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2 | | CAS: | 144025-82-1 | | MF: | C123H215N39O28S | | MW: | 2720.33 | | EINECS: | | | Product Categories: | | | Mol File: | 144025-82-1.mol |  |
| | H-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2 Chemical Properties |
| storage temp. | -15°C | | Sequence | Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 |
| | H-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2 Usage And Synthesis |
| Uses | PACAP-38 (16-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production[1]. PACAP is a potent activator of cAMP formation[2]. | | References | [1] Braas KM, et al. Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expression through activation of type I PACAP/VIP receptor isoforms. Ann N Y Acad Sci. 1996 Dec 26;805:204-16. DOI:10.1111/j.1749-6632.1996.tb17484.x [2] Lania A, et al. Mechanism of action of pituitary adenylate cyclase-activating polypeptide (PACAP) in human nonfunctioning pituitary tumors. J Neuroendocrinol. 1995 Sep;7(9):695-702. DOI:10.1111/j.1365-2826.1995.tb00811.x |
| | H-GLN-MET-ALA-VAL-LYS-LYS-TYR-LEU-ALA-ALA-VAL-LEU-GLY-LYS-ARG-TYR-LYS-GLN-ARG-VAL-LYS-ASN-LYS-NH2 Preparation Products And Raw materials |
|